FIELD: medicine.
SUBSTANCE: present group of inventions relates to neurology, and concerns the treatment of Alzheimer's disease. For this purpose, in addition to the acetylcholinesterase inhibitor, N-(2-(6-fluoro-1H-indole-3-yl)ethyl-(2,2,3,3-tetrafluoropropoxy)benzylamine or its pharmaceutically acceptable salt is introduced daily in a dose of 30–60 mg.
EFFECT: invention provides effective treatment by enhancing the effect of an acetylcholinesterase inhibitor.
13 cl, 13 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF 5-HT-RECEPTOR ANTAGONIST AND ACETYLCHOLINESTERASE INHIBITOR FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE IN SUBPOPULATION OF PATIENTS THAT ARE CARRIERS OF ApoE4 ALLELES | 2018 |
|
RU2776366C2 |
| MEMANTINE THERAPY FOR ALZHEIMER'S DISEASE OF LOW AND LOW TO MODERATE SEVERITY | 2005 |
|
RU2371173C2 |
| NEW CATECHOLAMINE-BASED PRODRUGS FOR USE IN TREATMENT OF PARKINSON'S DISEASE | 2018 |
|
RU2806075C2 |
| METHYLTHIONINIUM FOR TREATING SYNAPTOPATHIES | 2020 |
|
RU2835868C2 |
| METHOD OF TREATING DISORDERS USING SELECTIVE NR2B SUBTYPE NMDA RECEPTOR ANTAGONIST | 2009 |
|
RU2499598C2 |
| THERAPEUTIC INTERACTIONS OF LEUKOMETHYLTHIONINIUM | 2020 |
|
RU2834773C2 |
| USING THE ACETYLCHOLINESTERASE AND IDALOPIRDINE INHIBITOR TO REDUCE THE RISK OF FALLS IN THE PATIENTS WITH PARKINSON'S DISEASE | 2017 |
|
RU2742173C2 |
| SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-a]PYRIMIDINE-2,6-DIAMINES, SEROTONIN 5-HT RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS | 2010 |
|
RU2421456C1 |
| NEURODEGENERATIVE DISORDERS | 2015 |
|
RU2707191C2 |
| TETRAHYDRO-PYRAZOLO[1,5-a]PYRIDO-PYRIMIDINES - SEROTONIN 5-HT RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS | 2008 |
|
RU2391343C1 |
